Search This Blog

Thursday, November 1, 2018

AMAG Pharma Q3 top line down 2%; non-GAAP EBITDA down 34%


AMAG Pharmaceuticals (AMAG -15.5%) slumps on more than double normal volume after releasing Q3 results this morning that included a 1.7% drop in revenue. Highlights:
Revenues: $122.2M, down 1.7% due to supply constraints from third-party supplier of intramuscular injection products and by the entry of a generic competitor.
Makena sales down 17.8% to $80.2M. Faraheme/MuGard sales up 41.1% to $37.1M.
Net income: $30.8M (+120.2%); EPS: $0.89 (+120.6%); cash flow ops (9 mo.): $84.9M (-2.0%).
Non-GAAP EBITDA: $30.0M (-33.5%).
2018 guidance: Non-GAAP EBITDA: $115M – 125M from $95M – 115M.
Previously: AMAG Pharmaceuticals EPS of -$1.88 (Nov. 1)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.